Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-06-21FDA Approved: IMATINIB MESYLATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Mylan's original application for imatinib mesylate tablets, a generic version of Gleevec, for the same indications as the refer…
-
CLINICAL_TRIALS trial_result · 2017-06-07Clinical Trial Update: Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia [NA]
Interventional study aiming to improve adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2017-06-06Clinical Trial Update: Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies [Phase 1, Phase 2]
Phase 1/2 study evaluating plerixafor (AMD3100) as a stem cell mobilizer for transplantation from a sibling donor in various hematologic mal…
-
CLINICAL_TRIALS trial_result · 2017-05-30Clinical Trial Update: Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer [Phase 2]
Phase 2 trial evaluating a conditioning regimen with alemtuzumab, fludarabine phosphate, and total-body irradiation followed by cyclosporine…
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer [NA]
Clinical trial update reports results of a conditioning regimen using fludarabine and total-body irradiation followed by donor stem cell tra…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-05-19Clinical Trial Update: Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies [Phase 2]
Phase 2 study evaluating cyclophosphamide as GVHD prophylaxis after allogeneic peripheral blood stem cell transplantation in patients with h…
-
CLINICAL_TRIALS trial_result · 2017-05-17Clinical Trial Update: Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer [Phase 2]
Phase 2 trial evaluating haploidentical donor bone marrow transplantation in patients with high-risk hematologic cancers; results completed …
-
CLINICAL_TRIALS trial_result · 2017-05-15Clinical Trial Update: Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluating the use of nilotinib and imatinib after donor stem cell transplant in patients with acute ly…
-
CLINICAL_TRIALS trial_result · 2017-05-11Clinical Trial Update: Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells [Phase 1, Phase 2]
A terminated Phase 1/2 clinical trial evaluated haploidentical allogeneic transplantation with post-transplant regulatory T-cell infusion in…
-
CLINICAL_TRIALS research · 2017-04-28Clinical Trial Update: Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia [Phase 1]
This document reports a Phase 1 clinical trial evaluating a vaccine therapy for chronic myeloid leukemia.
-
CLINICAL_TRIALS withdrawal · 2017-04-20Clinical Trial Update: Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. [Phase 4]
Phase 4 trial evaluating nilotinib for newly diagnosed chronic myeloid leukemia in the accelerated phase has been withdrawn.
-
FDA approval · 2017-04-13FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Bosulif (bosutinib) from Pfizer, updating the product labeling in connection with the supple…
-
CLINICAL_TRIALS trial_result · 2017-04-06Clinical Trial Update: Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders [Phase 2]
Phase 2 clinical trial evaluating nonmyeloablative allogeneic stem cell transplantation for various hematologic disorders has completed.
-
CLINICAL_TRIALS trial_result · 2017-03-31Clinical Trial Update: Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [NA]
A terminated clinical trial evaluated mobilizing donor peripheral blood stem cells with plerixafor and filgrastim before donor transplant in…
-
CLINICAL_TRIALS trial_result · 2017-03-30Clinical Trial Update: Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies [Phase 1]
Phase 1 clinical trial update describing safety assessments for two infusion schedules of SNS-595 in patients with hematologic malignancies.…
-
CLINICAL_TRIALS trial_result · 2017-03-29Clinical Trial Update: Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation [Phase 1, Phase 2]
A Phase 1/2 clinical trial update reports completion of a study evaluating an investigational biological therapy in adults with advanced mye…
-
CLINICAL_TRIALS trial_result · 2017-03-07Clinical Trial Update: Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy [Phase 4]
Phase 4 trial assessing the efficacy and safety of nilotinib in chronic myeloid leukemia patients with suboptimal response to imatinib was t…
-
CLINICAL_TRIALS trial_result · 2017-03-06Clinical Trial Update: Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy [Phase 2, Phase 3]
This update reports the efficacy and safety outcomes of oral nilotinib (AMN107) in adults with chronic myeloid leukemia resistant or intoler…
-
CLINICAL_TRIALS research · 2017-03-03Clinical Trial Update: Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis [Phase 3]
A Phase 3 trial comparing cyclophosphamide with methotrexate plus a calcineurin inhibitor for GVHD prophylaxis in patients with various hema…
-
CLINICAL_TRIALS trial_result · 2017-02-28Clinical Trial Update: Tasigna in Glivec-resistant or Intolerant Patients in CML [Phase 4]
Phase 4 trial results of nilotinib (Tasigna) in chronic myeloid leukemia patients who are resistant or intolerant to imatinib (Glivec). The …
-
CLINICAL_TRIALS trial_result · 2017-02-28Clinical Trial Update: A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase [Phase 3]
Phase 3 trial evaluating nilotinib in adults with imatinib-resistant or intolerant chronic myeloid leukemia across blast crisis, accelerated…
-
CLINICAL_TRIALS trial_result · 2017-02-24Clinical Trial Update: Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase [Phase 4]
Phase 4 trial update on nilotinib as initial therapy for adults with Philadelphia chromosome/BCR-ABL-positive chronic myeloid leukemia in ch…
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase [Phase 4]
Phase 4 study evaluating nilotinib in adults with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis, accelerated ph…
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) [Phase 4]
A Phase 4 clinical trial comparing standard-dose versus high-dose imatinib mesylate in patients with chronic phase Philadelphia chromosome–p…
-
CLINICAL_TRIALS trial_result · 2017-02-20Clinical Trial Update: T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant [Phase 2]
Phase 2 trial of T-cell replete haploidentical donor hematopoietic stem cell transplantation with natural killer (NK) cell support in hemato…